News and Investors

Watch how we are developing glass microsphere technologies to treat cancer

Latest News

April 19th 2022

ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres® for treatment of liver tumors

Go to the Press Release»»

November 1st 2021

ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres® for treatment of liver tumors

Go to the Press Release»»

July 31st 2021

ABK Biomedical Affiliated Researchers Present Updated Eye90 microspheres® Scientific Advances at the 2021 Global Embolization Symposium Technologies Virtual Annual Meeting

Go to Scientific Presentations»»

Company News & Press Releases

ABK and University of Missouri Veterinary Health Center partner on new liver cancer trial for dogs

Halifax, Nova Scotia. March 7th, 2021. ABK Biomedical today announced that they entered into a partnership with…

Read about the study»»

ABK Biomedical partners with the CNIC to enhance patient care

Halifax, Nova Scotia. March 3rd 2020. ABK Biomedical, which is developing a transformative Eye90 microspheres® technology, with the potential to provide in-procedure prognostic dosimetry

Read the Press Release»»

ABK Biomedical Inc. Raises $30M USD in Series B Financing

Halifax, Nova Scotia. April 8th, 2019. ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing…

Read the Press Release»»

Strategic Partnership with the University of Missouri Research Reactor Center (MURR®)

Halifax, Nova Scotia. February 13th, 2019. ABK Biomedical Inc. (ABK) is pleased to announce a multi-year strategic partnership with the University of Missouri Research Reactor Center (MURR®)…

Read the Press Release»»

In The News

Eye90 microspheres Precision Dosimetry™ profiled in Physics World July 2022

 

MD Anderson Cancer Center post-doctoral fellow and ABK-affiliated researcher Dr. E Courtney Henry presented on recent advances in Y90 dosimetry at the 2022 American Association of Physicists in Medicine annual meeting.

The association recognized this research as a “Best in Physics” presentation. Click here to read more about this important advance and its impact on Y90 technology.

 

Precision Dosimetry

 

ABK Chief Medical Officer interviewed by Interventional News

 

Bob Abraham, MD, CMO at ABK Biomedical was interviewed by Interventional News in 2020 at The SPECTRUM Conference. Dr Abraham discussed the potential of using CT imaging with ABK Biomedical’s radiopaque microspheres to precisely map absorbed radiation dose.

Click the image for Dr Abraham’s perspective on this exciting advance in microsphere technology.

Co-Founder Discusses ABK’s Unique Microsphere Technology

 

ABK Biomedical Co-founder, Dr. Daniel Boyd, outlines the history of ABK, and the novel glass microsphere technologies the company is developing. 

ABK's Business Partners

ABK Biomedical is proud to partner with cutting-edge organizations and individuals with exceptional skills, scientific expertise, and the highest business ethics.

Investment Partners

Research Partners

Development Partners

MORE THAN JUST AN EMPLOYER

The ABK Biomedical Team

We are dedicated to encouraging a stimulating work environment offering an opportunity to significantly expand experience and skills by researching, developing, and commercializing cutting-edge medical device technologies with a mandate to effectively treat cancer.

ABK Biomedical is an equal opportunity employer offering competitive compensation packages.

Corporate Offices

Halifax Office (Main Office)
155 Chain Lake Drive
Unit 32
Halifax, NS B3S 1B3
Canada

T. 902.442.4009

 

Orange County Office
555 Corporate Drive 
Suite 105
Ladera Ranch, CA, 92694
USA

ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for the accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical Inc. may change the products mentioned, and their stage in development, at any time without notice. ABK Biomedical Inc. is a clinical-stage company engaged in the research and development of new medical devices. ABK Biomedical Inc. products are considered investigational products and are NOT FDA approved for use. Y90 radioembolization

Copyright 2022 - All International Rights Reserved